Jay M Mei

age ~59

from North Wales, PA

Get Report

Also known as:

Jay Ming Mei
Jianming Ng Mei
Jiam M Mei
Jian Ming Mei
Jian M Mei
Jianming M Mei
Jianming N Mei
Jain Mei
Jay Mie
Ng Mei Jianmi

Phone and address:: 1373 Perry Cir, North Wales, PA 19454
215 643-9009

Connected to:

Jay Mei Phones & Addresses

1373 Perry Cir, North Wales, PA 19454 • 215 643-9009
91 Sunrise Dr, Whippany, NJ 07981
Warrington, PA
Lansdale, PA
Frederick, MD
Chicago, IL
Morgan, NJ
Ellicott City, MD

Resumes

Founder And Chief Executive Officer

view source

Location:

North Wales, PA

Industry:

Pharmaceuticals

Work:

Antengene Corporation
Founder and Chief Executive Officer
Celgene Oct 1, 2008 - Apr 2017
Executive Director, Clinical Development, Hematology and Oncology
Novartis Apr 2006 - Oct 2008
Senior Director and Global Clinical Program Head; Clinical Development
Novartis Apr 2006 - Oct 2008
Senior Director, Oncology Clinical Development
Novartis Apr 2006 - Oct 2008
Director

Education:

University of Maryland - Baltimore 1989 - 1993
Doctorates, Doctor of Philosophy Xiang - Ya Medical College 1983 - 1989
Doctor of Medicine, Doctorates, Medicine

Skills:

Oncology
Clinical Development
Clinical Trials
Drug Development
Cro
Regulatory Submissions
Drug Discovery
Pharmacology
Neurology
Clinical Research

Jay Mei

view source

Location:

Greater Philadelphia Area

Industry:

Pharmaceuticals

Executive Director, Clinical Development At Celgene

view source

Position:

Executive Director, Clinical Development at Celgene

Location:

United States

Industry:

Pharmaceuticals

Work:

Celgene since Oct 2008
Executive Director, Clinical Development
Novartis Oncology Apr 2006 - Oct 2008
Senior Director/Global Clinical Program Head; Clinical Development

Us Patents

N-Substituted Tricyclic 1-Aminopyrazoles As Inhibitors For The Treatment Of Cell Proliferative Disorders
view source
US Patent:

7795440, Sep 14, 2010
Filed:

Jan 25, 2007
Appl. No.:

11/657912
Inventors:

Chih Yung Ho - Lansdale PA, US
Bengt Anders Brunmark - LaJolla CA, US
Stuart Emanuel - Doylestown PA, US
Dana L. Johnson - Upper Black Eddy PA, US
Donald W. Ludovici - Quakertown PA, US
Umar Maharoof - North Wales PA, US
Jay M. Mei - North Wales PA, US
Jan L. Sechler - Doylestown PA, US
Eric D. Strobel - Hatboro PA, US
Robert W. Tuman - Chalfont PA, US
Hwa Kwo Yen - Malvern PA, US
Assignee:

Janssen Pharmaceutica NV
International Classification:

A61K 31/416
A61K 31/4439
C07D 401/12
US Classification:

5462757, 5483595, 514338, 514405
Abstract:

The invention is directed to N-substituted tricyclic 3-AMINOPYRAZOLE derivatives, which are useful as inhibitors of platelet-derived growth factor receptor (PDGF-R) kinase, and methods for the preparation of said derivatives. The present invention is further directed to pharmaceutical compositions comprising the compounds of the present invention and to methods for treating conditions such as tumors and other cell proliferative disorders.

N-Substituted Tricyclic 3-Aminopyrazoles As Anti-Mitotic Tubulin Polymerization Inhibitors
view source
US Patent:

7816390, Oct 19, 2010
Filed:

Jan 29, 2008
Appl. No.:

12/021535
Inventors:

Robert A. Galemmo - Paoli PA, US
Dana L. Johnson - Upper Black Eddy PA, US
Umar S. M. Maharoof - North Wales PA, US
Jay M. Mei - North Wales PA, US
Robert W. Tuman - Chalfont PA, US
Assignee:

Janssen Pharmaceutica NV
International Classification:

A61K 31/416
C07D 231/54
US Classification:

514405, 5483591
Abstract:

The invention is directed to compounds having the following structures:.

N-Substituted Tricyclic 3-Aminopyrazoles As Inhibitors For The Treatment Of Cell Proliferative Disorders
view source
US Patent:

20040082639, Apr 29, 2004
Filed:

May 14, 2003
Appl. No.:

10/438152
Inventors:

Chih Ho - Lansdale PA, US
Bengt Brunmark - LaJolla CA, US
Stuart Emanuel - Doylestown PA, US
Robert Galemmo - Collegeville PA, US
Dana Johnson - Upper Black Eddy PA, US
Donald Ludovici - Quakertown PA, US
Umar Maharoof - North Wales PA, US
Jay Mei - North Wales PA, US
Jan Sechler - Doylestown PA, US
Eric Strobel - Hatboro PA, US
Robert Tuman - Chalfont PA, US
Hwa Yen - Malvern PA, US
International Classification:

A61K031/415
C07D231/56
C07D231/54
US Classification:

514/405000, 548/359100, 548/360100
Abstract:

The invention is directed to N-substituted tricyclic 3-AMINOPYRAZOLE derivatives, which are useful as inhibitors of platelet-derived growth factor receptor (PDGF-R) kinase, and methods for the preparation of said derivatives. The present invention is further directed to pharmaceutical compositions comprising the compounds of the present invention and to methods for treating conditions such as tumors and other cell proliferative disorders.

Immobilized N-Substituted Tricyclic 3-Aminopyrazoles For The Identification Of Biomolecular Targets
view source
US Patent:

20050130910, Jun 16, 2005
Filed:

Nov 10, 2004
Appl. No.:

10/986500
Inventors:

Chih Ho - Lansdale PA, US
Robert Galemmo - Paoli PA, US
Dana Johnson - Upper Black Eddy PA, US
Jay Mei - North Wales PA, US
Stanley Belkowski - Norristown PA, US
Richard Connors - Harleysville PA, US
International Classification:

A61K031/7056
A61K031/427
A61K031/422
A61K031/4162
C07H017/00
C07D417/02
C07D413/02
US Classification:

514023000, 514365000, 514374000, 514406000, 536017400, 548181000, 548215000
Abstract:

The present invention relates to immobilized N-substituted tricyclic 3-aminopyrazole compounds of Formula 1 as tools for the identification of bimolecular targets in cells of therapeutic significance, profiling the selectivity of compounds, prediction of possible related toxicities and exploration of mechanisms of action in biological systems for therapeutic indications related to compounds. These agents can be used to identify biomolecules with the potential to interact with the immobilized reagent. The identified biomolecule may be then be used as a therapeutic target, serve as a marker of drug action, or alternatively describe an untoward or toxic potential of the immobilized agent.

Methods Of Treating A Bruton's Tyrosine Kinase Disease Or Disorder
view source
US Patent:

20130109709, May 2, 2013
Filed:

Oct 26, 2012
Appl. No.:

13/661678
Inventors:

Heather Lounsbury - Framingham MA, US
Kathryn Stiede - Hollis NH, US
Bruce A. Silver - Dunkirk MD, US
Jay M. Mei - North Wales PA, US
Assignee:

CELGENE AVILOMICS RESEARCH, INC. - Bedford MA
International Classification:

A61K 31/505
A61P 35/02
A61P 35/00
US Classification:

514275
Abstract:

The present invention provides methods of treating, stabilizing or lessening the severity or progression of a disease or disorder associated with BTK.

Methods Of Treating A Disease Or Disorder Associated With Bruton's Tyrosine Kinase
view source
US Patent:

20170216432, Aug 3, 2017
Filed:

Nov 11, 2016
Appl. No.:

15/349045
Inventors:

- Pembroke, BM
Kenichi Takeshita - New York NY, US
Kenneth Foon - Summit NJ, US
Jay Mei - North Wales PA, US
International Classification:

A61K 39/395
A61K 9/00
A61K 31/4184
A61K 9/48
A61K 31/675
A61K 31/664
C07K 16/28
A61K 31/505
Abstract:

The present invention provides methods of treating, stabilizing or lessening the severity or progression of a disease or disorder associated with BTK.

Methods Of Treating A Bruton's Tyrosine Kinase Disease Or Disorder
view source
US Patent:

20160287588, Oct 6, 2016
Filed:

Jun 9, 2016
Appl. No.:

15/178299
Inventors:

- Cambridge MA, US
Heather Lounsbury - Framingham MA, US
Kathryn Stiede - Hollis NH, US
Bruce A. Silver - Dunkirk MD, US
Jay M. Mei - North Wales PA, US
International Classification:

A61K 31/506
A61K 9/48
A61K 9/00
Abstract:

The present invention provides methods of treating, stabilizing or lessening the severity or progression of a disease or disorder associated with BTK.

Methods Of Treating A Disease Or Disorder Associated With Bruton's Tyrosine Kinase
view source
US Patent:

20150139979, May 21, 2015
Filed:

Nov 19, 2013
Appl. No.:

14/084201
Inventors:

- Bedford MA, US
Kenichi Takeshita - New York NY, US
Kenneth Foon - Summit NJ, US
Jay Mei - North Wales PA, US
Assignee:

Celgene Avilomics Research, Inc. - Bedford MA
International Classification:

A61K 31/505
A61K 39/395
A61K 31/185
A61K 31/454
US Classification:

4241331, 514275
Abstract:

The present invention provides methods of treating, stabilizing or lessening the severity or progression of a disease or disorder associated with BTK.